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Perlecan, the large low-density proteoglycan of basement membranes:
Structure and variant forms. The complete primary structure of perle-
can, the large low-density proteoglycan of basement membranes, has
been deduced by cDNA cloning for the mouse and more recently the
human gene products. Mouse perlecan contains a 396 kDa core protein
with five distinct domains: a heparan sulfate attachment domain, a LDL
receptor-like domain, two different laminin-like domains and an
N-CAM-like domain. These domains are conserved to a striking degree
between mouse and human, including alternate splicing of the N-CAM
domain to generate variations of perlecan. These variant sequences also
appear to be highly conserved between mouse and human. The strong
conservation of these domains, including highly repetitive elements and
potential alternative splices, suggest they have vital functions.
Proteoglycans are present in almost all extracellular matrices.
They consist of a core protein containing covalently attached
glycosaminoglycan side chains at certain serine and asparagine
residues. Proteoglycans were first detected in basement mem-
branes by the presence of sulfate esters on their glycosamino-
glycan side chains [1—3]. Both chondroitin/dermatan sulfate and
heparan sulfate have been found in basement membranes,
although the proportion of these two glycosaminoglycans varies
between basement membranes produced by different cell types
[4].
Basement membranes are typically thin sheets of extracellu-
lar matrix between two different cell layers. They are, in native
tissues, present in relatively low abundance and are technically
difficult to isolate. The emergence of several different cell lines,
such as the Englebreth-Holm-Swarm (EHS) tumor [5] and
embryonal carcinoma derived endodermal cells [6], that pro-
duce basement membrane has made it possible to isolate the
components of basement membrane in sufficient quantities for
biochemical and immunochemical characterization. Perlecan, a
basement membrane proteoglycan containing heparan sulfate
side-chains, was first isolated and characterized [7] from the
EHS tumor, which had previously been shown to make colla-
gen IV [5] and laminin [8], and has since been shown to make
entactin (nidogen) [9]. Antibodies prepared against tumor per-
lecan were directed against the core protein of the proteoglycan
[7]. These antibodies reacted with all basement membranes in
various tissues, suggesting that this proteoglycan was produced
by different basement membrane-producing cells.
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Characterization of tumor perlecan showed it to consist of a
400 kDa core protein with three to four heparan sulfate side-
chains of 65 kDa each [10]. The pattern of proteolytic fragments
produced by trypsin and V-8 protease digestion indicated that
the core protein had considerable structure with regions rich in
disulfide bonds [11]. Rotary shadowed images of tumor perle-
can showed the core protein consisted of five to seven globules
in a linear array and three side chains emanating from a globule
at one end of the core protein [12, 13].
Antibodies against intact tumor perlecan have detected im-
munoreactive core proteins in sizes ranging from 95 kDa to 400
kDa in both the tumor and native basement membranes [10, 14].
This raised the possibility that perlecan may be produced in
several different sizes. However, the antibodies to perlecan
have detected only one precursor protein of 400 kDa [14—16].
This suggests that the smaller immunoreactive forms of perle-
can are derived as proteoglycan fragments of the largest form of
perlecan, the one with the 400 kDa core protein.
The antibodies to perlecan have also been used to obtain the
initial cDNA clones to perlecan from an expressing vector
library [17]. The initial clones to perlecan were to two different
domains of the core protein and were shown to contain matches
with amino acid sequence obtained from peptides derived from
the core protein, thereby confirming the identity of the clones.
The clones hybridized to a 12 to 14 kD mRNA, a message of
sufficient size to code for a 400 kDa core protein. This message
was detected in a variety of basement membrane producing
cells, which confirms the immunostaining of all basement
membranes with antibodies to perlecan. cDNA clones to the
entire perlecan message have been subsequently obtained using
the initial clones to screen primer extension and oligo dT
primed libraries [18]. This paper reviews the important features
of the domain structure of mouse perlecan based on the
deduced sequence from the clones and presents evidence for
alternate splicing of perlecan.
The complete deduced sequence of murine perlecan, a 396
kDa polypeptide, can be divided into five different domains.
Domain I, proposed as the probable heparan sulfate attachment
site, is otherwise unique to perlecan, showing no similarity to
other known sequences in other genes. Domain II is homolo-
gous to the LDL binding domain present in the LDL-receptor
and a growing family of other proteins. Domain III has homol-
ogy to the globule-rod regions of the laminin short arms,
showing the strongest similarity with the laminin A chain.
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Fig. 1. Dot-matrix comparison of the murine and human perlecan amino acid sequences. Comparisons were performed using the MacVector
software package (IBI) utilizing a minimum score of 30, a minimum length at 20 and the cam 250 mutation data matrix. Models based on sequence
homology and the domain location (1) are indicated for each molecule.
Domain IV is a highly repetitive region with numerous immu-
noglobulin-like repeats that show the highest similarity to
N-CAM. One of these repeats also separates domains II and III.
Domain V has three globular repeats very similar to the domain
o repeats in the laminin A chain and the equivalent segment of
the A chain homologue, merosin. Unlike the laminin, however,
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mper' - FPRvCTEtEFACHSYNECUALEYRCORRPDCRDMSDELHCEEP
I I I III IIIIIIIIIIIIIIIIIIIII I I 1111111111 I I
hper' I — FPRaCTEaEFACHSYMECUALEYRCDRRPDCRDI1SDELMCEEP
Upe I SsstpavgkvspLP I wPEaattppPPUTHgRQfLLPsvp
I :1 11:11 1111111111
UIgiSptfsI IvettsLPprPEtt imrqPPUTHaPQpLLPgsv
gPsaCGPQEAsChsGHC I PRDYLCDGQEDCrDGSDELgCa
I 111111 I: IIIIIIIIIIIIIIII 1111111
rP I pCGPQEAaCr'nGHC I PRDYLCDGQEDCeO6SDELdC9
repeats are separated from each other by EGF-like cysteine-
rich segments.
cDNA clones to human perlecan have been obtained [19] and
the recent completion of the human perlecan sequence [20]
allows for a comparison of these two species. The human
sequence also contains the same five domains, all of the
essential structural features have been conserved. A dot-matrix
comparison of the two species is shown in Figure 1. The two
essentially continuous diagonal lines indicate the conservation
of features between these two species, the most striking differ-
ence noted in this comparison is the presence of seven more
repeats in domain IV. This difference is probably due to
alternative splicing, which will be discussed in detail below.
The sequence of domain I, the sequence unique to perlecan,
is well conserved as shown in Figure 2. Even the signal peptide
has 16 of 21 amino acids identical between mouse and human,
and both sequences predict a valine as the N-terminal amino
acid. Domain I has 84% identical amino acids, as well as some
conservative substitutions. The three predicted heparan sulfate
attachment sites, SGD, are conserved. This SGD triplet is likely
very important since it is not found anywhere else in human
LDLr2
Fig. 2. Alignment of the signal peptide and
domain I of murine (mperl-, upper sequence)
and human (hperl-, lower sequence) perlecan
amino acid sequences. Identical amino acids
are indicated by the vertical bar. Conservative
substitutions are two dots. Gaps inserted to
improve alignment are shown by dashes.
Mismatched amino acids are shown in lower
case. The probable signal peptide is boxed.
The three probable heparan sulfate attachment
sites SOD are boxed and shaded. The
conserved potential N-linked oligosaccharide
site is underlined.
Fig. 3. Alignment of domain II from murine
(mperl-, upper sequence) and human (hperl-,
lower sequence) perlecan amino acid
LDLr 3 sequences. Identical amino acids are indicated
by the vertical bar. Conservative substitutions
by two dots. Mismatched amino acids are
shown in lower case. The LDL-receptor-like
repeats are indicated as LDLrI-LDLr4. The
LDLr 4 poorly conserved spacer region is also
indicated.
perlecan and is only present in one other place in mouse
perlecan. The sequences N-terminal to the first SGD are not
identical. The most notable difference, is the change of the
aspartic acid (D) two amino acids N-terminal to the first SGD to
serine in the human. This changes, in human, the first SGD to
a sequence that does not conform to the glycosaminoglycan
attachment signal acidic-X-SG-acidic. The human sequence
also shows an additional amino acid in this region. There is,
however, a stretch of 25 amino acids C-terminal to the SGD
sites in the human which is identical to mouse. This sequence,
because of its location, may play a role in glycosylation of this
portion of the molecule. This conserved segment also contains
the single N-linked glycosylation site present in domain I of
either species.
The LDL-receptor-like domain II, which consists of four
cysteine and acidic residue rich repeats, is also highly con-
served between mouse and human. Eighty-seven percent of the
amino acids in the four repeats are identical and near identity
between the first and last cysteines of each repeat (Fig. 3). The
"spacer" which separates the first and the second repeats in
this domain, however, is poorly conserved, only 36% (16 of 44)
mper I —
hperl—
Signal peptide
I1GqRAv6sLLLgLLLHaRLLAII 111111 (III 1111
I1GwRApGaLLLaLLLHgRLLA
LJTHGLRAYDGLSLPEDtETUTASrygUTyiIIIIIIIIIIIIIIIIIIIII II
LJTHGLRAYDGLSLPED i ETUTASqmr'NTh
SYLSODEDILADda 6 LG 6 vG 6 FQMUYFRALUNFTRSIEYSPQ
11111111:111 III 11111 :IIIIIIIIIIIIIIIIIIIIIIIII
SYLSDDEDmLADsi 6 16 G LG 6 FQF1UYFRALUMFTRSIEYSPQ
LEDAsaKEFREUSERUUekLEpEYr'K I PGDQ i USOUF I KELDGUUFUELDliii 11111111111: II II IIIIII:IIIIIIIIIIIIIIIIII
LEDA9eREFREUSEAUUdtLEsEY I K I PGDQvUSUUF I KELDGUUFUELD
UGSEGMADGsQ I QEvLhtUvSSGS I gpYUTSPwGFkFRRLGTI.JPQ
111111111 1111:1 1:1111: 11111 II 111111111
UGSEGMADGoQIQEmLIrU1SSGSvasYUTSPqGFqFRRLGTIJPQ
LDLr 1
Spacer
SPPPCEP ME F aCe MG HC ALKL URCDGD FOCEDA TDEAMCs vKq
IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII I
pPPPCEPMEFpCgMGHCALKLURCDGDFDCEDRTDEAMCpt Kr
PgEUCGPThFqCUSTMrC I PASFHCDEESDCPDRSDEFGCI1PP
1111111:1 11111 IIIIIIIIIIIIIIIIIIIIIIIIII
PeEUCGPTqFrCUSTHmC I PASFHCDEESDCPDRSDEFGCMPP
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mperl— OPCPD6HFYLEdSAsCLPCFCFGvTnUC '1IIIIIIIIIIIIIIIIItIII:tII 51—R1
hper I — OPCPDOHFVLEhSRaCLPCFCFG i TUC
QSs RFRDQ RLsFDQPnDFK6UHUTflPsQPOvPPLSSTQLQ I DPnLqEFQLUDLSRRFLUHDaFWALPkQFLOHKUDSV66 fLRVkURYELAROF1LEPU
II
QStr'RFRDQ RLrFOQPdOFKGUNUTIIPaQPGt PPLSSTQLQ I DP,LhEFQLUDLSARFLUHD,FWALPeQFLGHKUDSVOGsLRVnURVELAROF1LEPU
51- G
QkPOU i LU6A0VRLhSR6HTPThP6tLHQRQUQLSEEHI4UHES6APUQRAELQLaSLEAULLQTUVNTKI1ASUGLSD I vt1DITUTHt I HGRAHSUE
QrPDUvLU6AGYRL I SRGHTPIqP6aLNQRQUQFSEEHUUHESGAPUQRAE I LQVLqSLEAUL QTUYHTKI1ASUOLSD aF1DTTUTHaTsHOAAHSUE
ECRCP I OYSOLSCESCDAHFTRUPOOP VL6TCSGCnCHGHASSCDPUVOHCLHCQHHTE6PQCdKCKpGFFGDAtKATATaCRPCPCPV I OASRRFSDTC
III till lii 11111 I III II liii Ill III 1111 III lii 11111111 III liii I III II III Ill I I It III I III I 111111
ECRCPI OVSOLSCESCDAHFTRUPGGP VL6TCS0CsCH0HASSCDPUV6HCLHCQHNTE6PQCkKCKa6FF6DAmKATATCRPCPC—Y I DASRRFSDTC
Si- CR2-4
FLDTD6QATCDACAPOYTORRCESCAP6VE6HP I QP6GKCRPttQE I IJRCDERGS 6TS6Et
I hIll III III III II III I III III 11111111111 II 111111 1111 I III
FLDT000AICDRCAPOYT6RRCESCAP6YEOHP I QPOGKCRPvnQE I URCDEROSm6TSOEa
Fig. 4. Alignment of the first subdomain (SI) of the perlecan domain III murine (mperl-, upper sequence) and human (hperl-, lower sequence).
Identical amino acids are indicated by the vertical bar. Conservative substitutions by two dots. Gaps inserted to improve alignment are shown by
dashes. Mismatched amino acids are shown in lower case. Abbreviations are: CR1, first cysteine repeat; G, the globular segment; CR2—4, Cysteine
repeats 2, 3 and 4.
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CCTATCCCT6CCCCT606CCTOCCCCTCCI OICA6AATTOAGGCCTCATCCTCCACT6TG ACT6A660TCRCAT6CTOORTCTCRACTOT OT6GT6GCA66ACAOGCCCAC6COCAO6TC
P I P A P 0 P A P P U H I E A $ S S T U I E 0 H 11 L 0 I. H C U U A 6 Q A H A Q U 10
150 160 210 240
* * * * * * * * * S * *
ACATGOTACAA6CGT66666CAGCCTOCCA 6CCCO6CATCAOGTCC6C66CTCCCOCCTG TACAICTTRCA6GCTTCCCCA6CA6AT6CT OOAGAATAT6TGTOCA666CAOOCAAT666
1 11 V K A 6 0 S L P A R H Q U A 6 S A L V I I. 0 A S P A 0 A 0 E V U C A A 6 N 6 60
270 300 330 360
* * * * $ * * * * * * *
CAGGAAOCCACCATCACAGTCACOOTCACA C6CAACCAT6666CCAACCTT6CCTACCCC CC666TA6CAC6TCACCCATCC6CATT6AG TCCTCTTCCTCTCACGT66CTOA0660CA6
0 E A I I I U I U I H H H 6 A N L A V P P 6 S I S P I A I E S S S S H U A E 6 Q 120
390 120 150 480
* * * * * * * S * * * *
ACCCTG6ATCTAAATTOT6T6OTGCAAOGA CA6OCCCATGCCCA6OTCACATO6CACAA6 AGAO6A6OCAGCCT6CCT6CCCOOCACCA6 ACCCAT66CTCCCTGCT6C66CT6CACCA6
I L 0 L H C U U Q 6 Q A H A 0 U I U H K H 0 6 S L P A A H Q I H 6 S I. I. A L H 0 160
510 540 570 600
* * * S * * * * * * $ S
GTOTCTCCT6TO6ACTCA6OAOAATAT6TO T6CC6A6T6GA660A606CCC6TGCCTCT6 6AGA6CTCT6TCCTO6T6ACCAIT6A6CCT 6CA6OCTCT6CACCT6666TCATCCCTCCA
U S P U 0 S 6 £ V U C H U E 6 6 P U P L E S S U L V I I £ P A 0 S A P 6 U I P P 200
630 660 690 720
* S S * * S S S S S * *
OTCC6AATC6AATCRTCTTCCTCCCACOTO TCOOAA066CA6AGTCTGOATCTGAATTOC CTT6TTTCT666CA6ACICACCCCCROAIC TCCTOOCACAAGCOT66066CA6CCICCCTURIESSSSHU SEOQSLOLHC LVS6QIHPQI SUHKROOSLP 240
750 780 610 810
S S * S S S * S * * S S
OCCCOOCATCA6GTACATO6CTCAROACT6 AOACITCTCCA66TGACCCCAACIOACTCT OGAGAGTAT6TATQCC6AOIC6ICAOTOOC TC660CACCCAA6RA6CTTCTGTCCTO6IC
H H H Q U H 6 S A I. A L L Q U I P 1 0 S 6 E V U C A U U S 6 S 6 1 Q E A S U L U 280
S
ACCATCCAOCAOACCC
I I Q Q 1 265
Fig. 5. The complete cDNA sequence and deduced amino acid sequence of clones 2 and 25. Nucleotide base numbers are shown above the
sequence, amino acid numbers are to the left of the sequence.
Fig. 6. Alignment of the murine and human perlecan domain IV sequences. Identical amino acids are indicated by the vertical bar. Conservative
substitutions by two dots. Gaps inserted to improve alignment are shown by dashes. Murine repeats IgRI through IgRl5 and human repeats IgRi
through IgR22 are indicated. Murine repeat IgR5 is split to show optimal alignments. The sequence of clones 2 and 25 (2/25) is also shown aligned
with the human sequence. The completely conserved residues are indicated by vertical shaded bars. The two extraneous cysteines are boxed and
shaded.
of the amino acids are identical, most of these occurring in a in mouse vs. 8 in human). The human sequence of domain II
segment of 12 amino acids. The length of the segment is also lacks a potential N-linked oligosaccharide site found in
preserved, but the number of prolines is lower in the human (12 mouse perlecan.
migRi
111111 I I I I III liii lI 11111 I I I:I 1111111 I I I I: I 11111111111 I II I I I II I+I I I I I I I I I I I I 11111111
hIgAl QUVTPPreSlQRSFWQTVTFTUAlGUPuPfi iWRLNI16HiPsqPRUTvTSE66R6TLI iRDUKE,DQ6RYTERflNaR6flUFGiPD6ULELUPQRa
ml gR2 SLEUQ HPSRSUUPQOOPHSLRCDVSOSPPHY FYUSREDORPLPSSAQQRHQO SELHFPSUQPSDAOUY ITfHL I HTSIISRAELLUAEAPSKP
IIIIIIII:IIIII:IItI III IIt:1111111I1 111111 IIIIIIIIIIIIIIIII1:IIIIIII•IIIIIIIIIIIIIII
hi gR2 PLUUEUHPARS I UPQ.DSHSLRQUS6ROPHV FYUREO6RPUPSOTQQAHQG SELHFPSUQPSDAQUY I !I1.ThLHRSHTSRAEL.LUTEAPSKP
mlgR3 I IWTUEEQRSQSURPOLRDVTFI e:IAKsKspAYTLUUTRLHHGKLPsRR I1OFPIG ILlI RHUQPSDRGTYUç•.TGSHflFRflDQDTRTLHUQUSGTST
iIiIiIIIIIIIIIiIIiIIIiIiIiIIIIIIIIIIIIIIIIIIIIIIII iIiIiiiiiiIiiiiIiIIiiIiiiiliiIIIIIIl
hi gR3 I TUTUEEQRSQSURPADUTF I ITAKSKSPRVTLUUTRLHH6KLPTRA I1DFNG I LII RHUQLSDRGIVUeJOStInFAnDQGTATLHUQASOTLS
ml gR1 APUAS I HppQLTuQp&QQAEFR:snTNp TPI1LEUI GGPS6QLPRKA 01 HMO I LALPA I EPSDQQQYLC.RRLSSRGQHUARAMLQUHGGS
IIIIIIIIIIIIIIIIIII.IIIIIIIIIIIIIIIIIIIIIIII IIIIII:IIIIIIIIIIIIIIIIIIII:I:IIIII
hi gRi APUUS I HPPQLTUQPQLAEFRISATGSP TPTLEIIT66PGOQLPAKA 01 HG6 I LRLPRUEPTDQRQYLCRAHSSR000UARAULHUH000
mIgR5 GPRUQUSPERTQUHEc.RTURLVeRRAOUP SRSITWKE GGSLP
IIIIIIIIIIIIIII:lIIIIIIIIIII II IIIII 11111
hI gR5 6PAUQUSPERTQUHRRTURLVRAAOUP SRI I TIRKE GGSLPPQA RSERT Dl fILL I PA I TTADAOFYLc:UATSPAGTAQAR I QUUULSASDRS
hi gR6 QPPVK I ESSSPSUTEQTLDLNUUA6SA HAQUTUVAR GGSLPHHT QUHGS ALRLPQUSPADSGEYUCRUENSGPKEAS I TUSULHOTHSOPSVTPUPOS
2/25— PIPAPOP
hi gAl TAPIR I EPSSSHUAEQTLDLt1UUP6QA HAQUTUIKR GOSLPRRH QTHGS LLRLHQUTPRDSGEVuC:HuuoTsopLEAsuLuT I EASU $ PGP
2/25— APPUR I EASSSTUTEHMLDLNCUUA6OA HRQUTUVKR GGSLPARH OURGS RLY I LQASPADA6EYURA6H6QEAT I TUTVTRKHGAHLAVPPGS
111111 111111:111 ilIllil IIIIIIII 11111111 11111 tIII:IIIlIItI:IIIIIIIt 111111 :111111111
hi gR8 I PPUA I ESSSSTUAEQTLDLSLJURGQR HAQUTUVKR GGSLPARH QURGS RLV I FQASPHDR6QVUIRASH6I1EAS I TUTUTGTQGRNLRVPAGS
2/25— TSP IRIESSSSHUAEOTLDLHC:UUQGOA HAOUTUHKR GGSLPAAH QIHGS LLRLHOUSPUDS6EVURUEGOPUPLESSULUTlEPASAP——6U
I 11111 111:11 ILII I IIjI I I I II tIIII I 11111:11 (1111 1111 1 11111111 II I I 1111 11111111111 II
hIgR9 TQPIRIEPSSSQUREQTLDLH:LIUP6QS HAQUTWIKR GGSLPUAH QTHGS LLRLVQRSPRDS6EVURUL6SSUPLEASULUTIEPA6SUPALGU
2/25— I PPUR I ESSSSHUSEQSLDLI1CLUS6QT HPO I SUHKR OGSLPARH QUH6S RLRLLQUTPTDS6EVURUUS6S6TQEASULUT I QQT
I 11111111:1 I1.I II III I II I I: :II I 11111111 (liii 111111111 11111 I:I II 11111111111 III
hi gAl 0 TPTUR I ESSSSQUAEcQTLDLMc.LUAOQR HAQUTUHKR GOSLPARH QUHGS ALRLLQUTPADS0EVURUUGSS6TQEASULUT I QQRLSGSHSQOU
hIgRi 1 AYPURIESSSASLAN4HTLDLNCLUASQA PHTITUVKA DOSLPSAH QIUOS RLRIPQUTPADSGEYUHUSH0AGSRETSLIUTIQGSGSSHUPRU
ml gAS FRH QRH6S RLRLHHI1SURDSGEVUCRRIIIIHIDRQETSIIII$USPSIHSPPAPAS
111111 1111 IIIIIIIIIIIIIIIIIII 111111111 11111
hIgRI2 SPPIRIESSSPTUUE.QTLDLHCUUARQP QRI ilYKR GOSLPSRH QTHGS HLRLHQflSURDSGEVUtRRNHHiDRLEASIUISUSPSAGSPSAP0S
ml gR6 PAP IA $ EssssRuAE:oTLDLNuupoHA HAQuTUHKR GQSLPTHH QTHOS RLRLVQUSSADSGEYUCSULSSSGPLEASULUS I —TPAAANUH I ——POU
IIIIIIIII:IIIjIIIIIIIII:IIIIIlIIlIIIII 111:11 IIIIIIIIIIIIIJ.I:IIIIIIiIIIII II: III
hI gAl 3 snp IA I ESSSSHUAEUEILDLHC:UUPOQR HRQUTU*IKR GGSLPSYH QTAQS RLRLHHUSPADSGEYU$RUF16SS6PLEASULUT I ERSOSSAUHUPAPOG
algAl UPP IA I ETsssAuAE:oTLDLsuupoQA HAQUTUHKA GOSLPAOH QUHGH nLRLHRuspADsoEvse:QUTOssOTLERsULUT I EASEPSP I PAPGL
IlIIIIIIIIIIIIJIIIIIIIIIIIIIIII.1IIIIIIIIIIII :IIIIIIIIIIIIIIi.IIIIlIIlIIIIllIlIIlllIlIIII
hi gAl 4 APP IA I EPSSSAUAEU.QTLDLKCUUPOQA HAQUTIIIIKR GOHLPARH QUHOP LLALHQUSPADS0EYSIUT0SSGTLEASULUT I EPSSPGP I PAPOL
ml gR8 AQPVV I ESsssHLTE:pTUDLKcUUP6QA HAQUTUIKR BSSLPARH QTHOS LLRLVQLSPADSGEVUCQUAGSSHPEHEASFKLTUPSSQNSSFALR
III;IIIIIII:IIJII:IIIIIIIIIIIIIiIIIIIIIIIIIIII III::IIIIIIIIIJ II II:lIII:IIII;
hIgRl5 AQPIVIEASSSHUTEQTLDLNCUUP0QA HAQUTIWKR OOSLPARH QTHOS QLRLHHUSPADSGEVURARGGP6PEQERSFTUTUPPSEGSSVALR
mIgR9 SPUISIEPPSS1UQQQDASFKLIHE6AnPIKUEUflRDQELEDHUHISPHGS $ ITIUAPGPATflEPTACUASPIUVOflRQSUUPILSUHOP
IIIIII:IIIIIIIIIIIIII.1:III:IIII:IIII;IIIIIIIIIIIIII 11111 I JIIIIII:IIIIIIIIIIII
hIgAl6 SPUISIDPPSSTUQQQDASFKiIJHD0AAPISLEUtTRHQELEDNUHISPHGS I ITIUOTRPSHHOTVAUASNAY0UAQSUUNLSUH0P
mlgRlO PTUSULPE6PUHUKflDITLEISSGEP RSSPRUTAL—6lPUKLEPRflF0LflHSHRflLK$ASUKPSDA6lVUCQAQHAL0IAQKQUELIUDT0TURP0
IIIIIIIIIIIII:I:III1::IIIIIIII.II: IIIII:III:II:IIIIIIIIIIIIIIIIIIIIIIIII:IIIII:III
h$gRll PTUSULPE6PUUUKUOKAUTLEIUSAGEP RSsAAU?1RISSTPAKLEQRTY6LflDSHlULQlSSRKPSDAGTVUiLAQHALGTAQKQUEUIUDTGAflAPG
mlgRl 1 TpQUQUEESELTLEA:HTATLHSAl0Kp PPTIHU'SKL RRPLPUQHRIEOIIT LUIPRUA000SOQVIeHATNSROHTEAIUULHUES
111111 III:IIIIIII:1IIIII IIIIIIIIIIIIII:It;I I:IIIIIIIIlIllIlII III III::IIIII
hIgRl8 APQUQAEEAELTUEa:HTATLRSAT0SP ARTIHUSKL RSPLPUQHRLEGDT LI IPRUAQQDS0QYI$HATSPA6HAEATI ILHUES
mIgRl2 PPVATI IPEHTSAQPHLUQLQ:LAH0TP PLTVQUSLU GOULPEKAUURIIQL LRLEPIUPE0S0RVRI.QUSHRU6SAERFAQULUQ0SSSHLPDTSIPG0S
11111 :IIIII IIII:IIIIIIIII:IIII II I 11:1 I::I IIIIIIII1II:IIIIIIIII:IIII 11111111
hi gRI 9 PPYATTUPEHRSUQATUQLQLAHGIP PLTFQNSRU GSSLPGRATARHEL LHFERAAPEDS6AYRIRUTNKU6SAEAFAQLLUQGPP0SLPATS I PROS
mIgRl3 TPTUQUTPQLETRHIfiSUEFH:AUPHER OTHLRU1KE 600LPPGHSUQDOU LRIQHLDQI1QOTVUPAH6PWOQAQATAQLIUQALP
IIIIlIIIIIII:IIIIIIIiIII:III:II:IIIIIIIIIIIIIIII IIIIIIIIIIlIIII;IIIllIIlIIllI::IIII
hIgR2O TPTUQUTPQLETKSIASUEFHIJIUPSOR 6TQLRNKE GOQLPPOHSU000U LAIQHLDQGTYICQAH6PU6KAQRSRQLUIQRLP
mIgRil SULU1UATSUHSUUUHSUEFECLRL6DP KPQUTUSKU GGHLAPGIUQSOTI IRIRHUELRDAGQVRtAATIIRROTTQSHULLLUQ
IIIII:IIII:IIITIIIIIjlIIIIIIIIIIIIIIIIIIIIIIIII: :IIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
hIgA2l SULIHIRTSUQIUUUHAUEFELALGDP KPQUIUKU GGHLRPOIUQSGOU URIRHUELRDAGQVRTRTHAAGTTQSHULLLUQ
mlgAl5 ALPQ I STPPE I RUPASAAUFPCJ1RSOYP IPA I TUSKU DODLPPDSALEKNI1 LMLPSURPEDA0TYU1ATHRQOKUKAFAYLQUP
lIIIIII:IIIIIIiIIIIIIlIIIIIIIIII
hI gR22 ALPQ I SflPQEURUPASAAUFP:I ASGYP TPD I SUSKL DGSLPPDSRLEHHI1 LI1LPSUQPQDROTVUCJATPIAQOKUKAFAHLQUP
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Fig. 7. Northern analysis of perlecan minor transcripts identified by
long exposure. Ten micrograms EHS and M2 mouse melanoma poly
A + RNA was separated by denaturing agarose gel electrophoresis and
transferred as described previously [2]. Blots were probed with the
region encoding the LDL-receptor-like region or murine perlecan. Right
side, overnight exposure, left side, 5 day exposure of same blot.
Positions of the 28s and 18s ribosomal RNA are indicated. Arrows
indicate the major transcript and larger minor bands.
The single N-CAM-like repeat that separates domain II from
domain III is conserved with 90% of the amino acids identical,
although the human is two amino acids longer than the mouse.
Domain III, which shows homology to the short arm of
laininin A chain, is also highly conserved, with 88% of the
amino acids identical and only two gaps needed to align the two
sequences, one occurring at the end of the domain on the border
with domain IV. An alignment of a representative subdomain is
shown in Figure 4. Essentially all the structural features are
identical, the number and position of the cysteines and the
cysteine-free globular segments. There are two conserved po-
tential N-linked glycosylation sites in this domain and human
perlecan has one additional site in this domain.
Comparison between domain IV of the mouse and human
shows a clear difference, the human sequence contains seven
more N-CAM-like repeats than the murine sequence (Fig. 1).
This difference is probably due to alternative splicing occurring
in this region of perlecan. Domain IV in both mouse and human
may show extensive variability in the number or exact sequences
of the N-CAM-like repeats due to alternative splicing. Both mouse
and human do show, however, two extra cysteines at either end of
this domain and these can probably be linked together.
Much of the evidence for alternative splicing comes from our
cloning efforts in murine tissues [17, 18]. Initial screening of
EHS derived libraries yielded one small clone (clone 2) which
was extended to 856 bases by primer extension (clone 25). The
complete coding sequence for clones 2 and 25 (2/25) is given in
Figure 5. Unlike another small clone (BPG 1) derived from this
library [17], clones 2/25 do not perfectly align with the com-
pleted sequence. However, it recognized the same mRNA on
Northern blots, and codes for a sequence nearly identical to
repeats mIgR5-mIgR8, which are nearly identical to each other.
It was unlikely that these clones were derived from a closely
related protein since gene localization studies in both the human
and mouse used clone BPG 7, which contains these highly
similar repeats and cross hybridizes, and these localizations did
not indicate the existence of a separate gene encoding for such
a similar protein.
Further evidence for alternative splicing comes from the
human sequence for perlecan, which shows an additional seven
repeats in domain IV, bringing the total to 22. An alignment of
the murine and human domain IV is shown in Figure 6. Note
that murine and human repeats IgR2, 3, and 4 align quite well.
However, only the first half of the murine mIgR5 repeat aligns
well with the human hIgR5. The second half of mIgR5 aligns
best with the second half of hIgRl2. In the following repeats,
the murine mIgR6-mIgRl5 align well with the human hIgRl3-
hIgR22. It has been suggested [20] that this split in alignment
could represent an alternative splice site, in keeping with the
location of the exon-intron boundaries in the N-CAM repeats
being located in the middle of each repeat. The three repeats of
the potential murine alternative splice sequence encoded by
clones 2/25 aligns well with the human segments hIgR8-hIgRlO,
indicating that these alternative splice segments also appear to
be well conserved between human and mouse.
There are four conserved potential N-linked glycosylation
sites in domain IV. Two of these are in the relatively variant
repeat mIgR9/hIgRl6. In regions where overlapping sequence is
available, both human and mouse perlecan have one additional
non-conserved potential N-linked glycosylation site.
The insertion of such large segments of mRNA (approximate-
ly 2 kb) should be evident on northern analysis. Northern
analysis has indicated a single prominent band of the same size
for both human and mouse. Thus it appears that one of these
forms is relatively rare. We have noted, however, that certain
tissues, such as the munne melanoma M2 cells, show detect-
able bands larger than that of the predominant band but only
upon much longer exposure (Fig. 7). These bands may repre-
sent the larger forms of perlecan. It should be noted that these
are not discrete bands. This could be due to degradation or this
may also indicate a high variability in the splicing of perlecan.
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Fig. 8. Alignment of murine (mperl-, upper sequence) and human (hperl-, lower sequence) perlecan domain V amino acid sequences. Identical
amino acids are indicated by the vertical bar I. Conservative substitutions by two dots. Gaps inserted to improve alignment are shown by dashes.
The larger transcripts are also much more predominant in the
M2 cells than in the EHS tissue, indicating that these alternative
messages may also be tissue or cell specific.
The addition of seven extra N-CAM repeats would result in a
substantially larger domain IV. However, the positions of the
extraneous cysteines (in the first repeat, mIgR2/hIgR2 and the
third from last repeat, mIgRl3/hIgR2O) are conserved. Assum-
ing these two cysteines are linked, the overall dimensions of the
molecule are not likely to change in the larger forms, though
clearly the size of the domain IV globule would be much larger.
The function of these minor forms, or for all of domain IV, is
not yet clear. However, the strong conservation of the highly
repetitive segments, as well as the more variable segments and
even the alternative splice regions, indicate an important role
for this domain and its variants.
The sequence of domain V is highly conserved as well (Fig.
8). There is but a single segment of 19 amino acids with
substantial variability from one species to another, but this may
be due to a frame shift errors as the cDNA segments encoding
these sequences show portions with near identity in other
reading frames (not shown). Excluding this segment, the overall
similarity in domain V is 91% in the amino acids. Many of the
substitutions are conservative, and the C-terminal sequence is
identical. The three potential N-linked glycosylation sites in
domain V are all conserved.
A graphical picture of the similarities and differences between
the human and mouse perlecan sequences is shown in Figure 9.
The major differences being in the spacer segment located
between the first and second LDL-receptor-like repeats in
domain II (arrows), and the alternative splice segment present
in the human but absent in the contiguous clones for murine
perlecan. The location of the clones encoding potential munne
alternate splice segment relative to the human alternate splice
region is also shown.
In conclusion, the high degree of conservation between
mouse and human perlecan in all five domains suggests that
these domains play important roles in the structure and function
of basement membranes, in addition, minor variants of perlecan
appear to be generated by alternative splicing. These variants
also appear to be well conserved between mouse and human,
indicating such variants may have important functions as well.
This suggests that the core protein of perlecan has many other
ftinctions besides that of carrying and localizing the heparan
sulfate chains within the basement membrane. It is quite probable
mper I —
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Splice site
Fig. 9. Graphical comparison of the murine and human perlecan. The alternatively spliced region is indicated, as is the position of clones 2/25
relative to the human splice region sequence. The poorly conserved spacer region between the first and second LDL-receptor-like repeats is
indicated by arrows. The heavy chains indicate the probable attachment sites for heparan sulfate. The smaller branched structures indicate possible
N-linked oligosaccharide attachment sites, those shown solid are conserved, those shown open are not conserved. There is one site in the human
sequence where there is no aligning sequence in the mouse.
that the core protein of this molecule plays a major structural role
in the formation and maintenance of basement membranes.
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